Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane in COPD patients

(2042) Views  (422) Full article downloads

Authors: Zoë L Borrill, R Cerys Starkey, S Dave Singh

Published Date May 2007 Volume 2007:2(1) Pages 71 - 76

DOI: http://dx.doi.org/10.2147/COPD.S

Zoë L Borrill, R Cerys Starkey, S Dave Singh

Medicines Evaluation Unit, Langley Building, Manchester University Wythenshawe Hospital, Manchester M23 9LT, UK

Abstract: The reproducibility of exhaled breath condensate (EBC) mediators is not well documented in chronic obstructive pulmonary disease (COPD). This study assessed within assay (WA), within (WD) and between day (BD) reproducibility of EBC leukotriene B₄ (LTB₄) and 8-isoprostane. Three EBC samples were collected from 24 COPD patients separated by 1 h and 1 wk, to assess WD and BD reproducibility. WA reproducibility was assessed by sample analysis by enzyme immunoassay in triplicate. WA coefficient of variation for LTB₄ and 8-isoprostane (18.2% and 29.2%, respectively) was lower than corresponding values for WD (47.7% and 65.3%, respectively) and BD (75.7% and 79.1%, respectively). Repeatability coefficient for 8-isoprostane and LTB₄ assays were 18.6 pg/ml and 13.2 pg/ml, respectively. Group mean differences for WD and BD were small and statistically nonsignificant. Using the Bland Altman method, there were wide limits of agreement for WD (–51.6 to 47.2 for 8-isoprostane and –31.8 to 31.4 for LTB₄) and BD reproducibility (–61.4 to 75.7 for 8-isoprostane and –29.3 to 38.6 for LTB₄). This is the first study to fully report the variability of EBC 8-isoprostane and LTB₄ in COPD. WA variability and group mean changes were small. However, we observed considerable WD and BD variability for these biomarkers.

Keywords: chronic obstructive pulmonary disease, exhaled breath condensate, leukotriene B₄, 8-isoprostane, reproducibility.